SynOV1.1

DB17539InvestigationalGene Therapies

SynOV1.1 is an investigational cancer immunotherapy developed by SyngenTech. It is a recombinant oncolytic adenovirus, controlled by synthetic gene circuit, encoding the human immunostimulating factor cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF).... SynOV1.1 is under investigation in clinical trial NCT04612504 (Synov1.1 Intratumoral Injection Study).

Code names: SynOV1.1

What you can answer from here — as of April 02, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of SynOV1.1, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account